Acaca Antibody is a monoclonal or polyclonal antibody designed to specifically bind to ACACA, the enzyme encoded by the ACACA gene. ACACA catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the rate-limiting step in fatty acid biosynthesis .
Acaca Antibodies are widely used for:
Western Blot (WB): Detects ACACA in lysates from human and mouse cell lines (e.g., A431, HCT-116, HepG2, C2C12) .
Immunohistochemistry (IHC) and Immunocytochemistry (ICC): Localizes ACACA in tissue sections and cultured cells .
Enzyme-Linked Immunosorbent Assay (ELISA): Quantifies ACACA levels in biological samples .
| Cell Line | Species | Band Size (kDa) | Citation |
|---|---|---|---|
| A431 (human epithelial carcinoma) | Human | 250 | |
| C2C12 (mouse myoblast) | Mouse | 250 |
ACACA inhibition reduces lipid accumulation by activating the AMPK-PPARα-CPT1A pathway, improving mitochondrial function in non-alcoholic fatty liver disease (NAFLD) models .
In pancreatic alpha-cells, ACACA knockout (gluACC1KO) impairs glucagon secretion during hypoglycemia, highlighting its role in metabolic homeostasis .
ACACA is overexpressed in cancers such as colon carcinoma, where it is a potential therapeutic target. Citrus lemon-derived nanovesicles targeting ACACA show antitumor effects .
Studies using Acaca Antibodies revealed altered lipid metabolism in hepatocellular carcinoma cells exposed to diethylnitrosamine .
Lipids in Health and Disease (2021): ACACA’s involvement in hepatocellular carcinoma lipidosis .
Molecular Medicine Reports (2023): Proteomic studies of ACACA in bacterial biofilms .
Research is exploring ACACA inhibitors (e.g., targeting BC/CT domains) for metabolic disorders and cancer . Antibody-based diagnostics may enable personalized therapies by correlating ACACA levels with disease progression .